Actuate registers Phase 1/2 trial of oral elraglusib in advanced solid tumors

Actuate Therapeutics had one clinical trial registry update for the week of July 20, 2026.

• The study, "Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of Elraglusib Oral Tablets in Adult Participants With Advanced Solid Tumors," was listed as not yet recruiting, with an estimated start of October 2026 and estimated primary completion in July 2029¹. Actuate Therapeutics is the lead sponsor of the industry-funded study, registered under the ID Actuate 2601. The trial plans to enroll an estimated 100 participants, with elraglusib administered as 250 mg tablets once daily with food in 21-day cycles¹. Its primary objective is to determine the maximum tolerated dose or maximum administered dose and dose-limiting toxicities of elraglusib tablets given daily¹.